RecruitingNot Applicable

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

United Kingdom30 participantsStarted 2025-09-09

Plain-language summary

To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis * Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone) * Subject aged \> 18 years * Able to willingly give consent Exclusion Criteria: * Co-morbidities currently requiring enteral feeding * Weight loss \> 10% in preceding 3-6 months * Significant musculoskeletal issues that may impact muscle mass * End of life care (expected \< 6 weeks left to live) * Previous anti-fibrotic use * Currently on \> Prednisolone 10mg daily * Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM) * Heart failure * Pregnancy

What they're measuring

Recruitment of patients to study

Timeframe: For study recruitment window of 6 months

Implementation of study protocol

Timeframe: For the 6 month recruitment window

Feasibility of collection of data

Timeframe: For the the study recruitment window of 6 months

Acceptability of use of BIA and muscle ultrasound

Timeframe: To be performed at baseline visit and 4 month visit

Trial details

NCT IDNCT07332117

SponsorRoyal Brompton & Harefield NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04

Contact for this trial

Jessica Dr Raja

07955229245 jessica.raja2@nhs.net

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis (IPF) trials